ONCOLYTICS BIOTECH INC 8-K

What Happened On March 19, 2026, Oncolytics Biotech, Inc. (ONCY) filed a Form 8‑K to announce that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting. The accepted abstracts report data from Cohort 1 of the GOBLET study in metastatic pancreatic ductal adenocarcinoma patients and from the AWARE‑1 study in breast cancer patients. A press release dated March 19, 2026 was attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: March 19, 2026 (Form 8‑K, Item 8.01: Other Events; Item 9.01 exhibits included).
• Studies referenced: GOBLET (Cohort 1) — metastatic pancreatic ductal adenocarcinoma; AWARE‑1 — breast cancer.
• Event: Two abstracts accepted for presentation at the AACR Annual Meeting.
• Corporate filing: Press release attached as Exhibit 99.1; Form 8‑K signed by CFO Kirk Look.

Why It Matters Acceptance of abstracts at a major scientific meeting like AACR highlights progress in Oncolytics’ clinical program and increases visibility of its clinical data among researchers, clinicians, and investors. While the 8‑K does not report financial results or changes in management, the presentations may influence future clinical and commercial interest in Oncolytics’ assets and could be a catalyst for investor attention depending on the data presented.